News articles about Innoviva (NASDAQ:INVA) have been trending somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Innoviva earned a news sentiment score of 0.06 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.3423986560843 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
INVA has been the topic of a number of research reports. Cowen and Company set a $16.00 price target on shares of Innoviva and gave the company a “buy” rating in a report on Monday, October 23rd. ValuEngine upgraded shares of Innoviva from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Zacks Investment Research upgraded shares of Innoviva from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a report on Wednesday, October 25th. Robert W. Baird reiterated a “hold” rating and issued a $13.00 price target on shares of Innoviva in a report on Tuesday, October 24th. Finally, Stifel Nicolaus reiterated a “hold” rating and issued a $15.00 price target on shares of Innoviva in a report on Friday, July 28th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company’s stock. Innoviva currently has an average rating of “Hold” and an average target price of $13.60.
Innoviva (NASDAQ INVA) traded up $0.29 during trading on Friday, hitting $12.59. 835,411 shares of the stock were exchanged, compared to its average volume of 1,058,770. Innoviva has a 12-month low of $10.07 and a 12-month high of $14.87. The company has a debt-to-equity ratio of -2.59, a quick ratio of 7.31 and a current ratio of 6.71. The company has a market cap of $1,360.00, a P/E ratio of 14.26 and a beta of 2.52.
Innoviva (NASDAQ:INVA) last posted its earnings results on Wednesday, October 25th. The biotechnology company reported $0.21 earnings per share for the quarter, missing analysts’ consensus estimates of $0.34 by ($0.13). Innoviva had a negative return on equity of 33.55% and a net margin of 52.91%. The business had revenue of $48.64 million during the quarter, compared to the consensus estimate of $57.18 million. During the same quarter last year, the firm earned $0.13 earnings per share. The business’s quarterly revenue was up 46.0% on a year-over-year basis. sell-side analysts forecast that Innoviva will post 1.08 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This news story was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://sportsperspectives.com/2017/11/10/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-innoviva-inva-stock-price.html.
Innoviva Company Profile
Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).
Receive News & Ratings for Innoviva Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva Inc. and related companies with MarketBeat.com's FREE daily email newsletter.